The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst
: Thanks for taking the questions. Maybe I have two quick ones. First, what trends are you seeing in terms of adoption of the solid tablet formulation
of LIVMARLI and what percent of sales are for that versus the liquid? And then for volixibat, what are you thinking in terms of the appropriate price
analogs, especially after we've seen a significant increase in rare orphan disease prices perhaps over the last year, particularly for conditions that
perhaps are less prevalent than PBC and more aligned with PSC.
Thank you.
Question: Gavin Clark-Gartner - Evercore Inc - Analyst
: Hey guys, thanks for taking the question. Just had one. What's your expectation for Paragraph four filers. Maybe just helpful to lay out your confidence
in your whole IP portfolio, especially around the method [patents] and including (inaudible).
Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
NOVEMBER 04, 2025 / 9:30PM, MIRM.OQ - Q3 2025 Mirum Pharmaceuticals Inc Earnings Call
Question: Joseph Thome - TD Cowen - Analyst
: Hi there, good afternoon. Thank you for taking my questions and congrats on the progress. Maybe on the PSC study now that, that one is fully
enrolled, are you able to talk a little bit about the baseline criteria of the patients that were enrolled, especially as it relates to the population that
was studied in the interim analysis population.
And maybe second, can you also discuss a little bit the importance of hitting on quality of life measures or bile acid in addition to ITCH, and will
that -- those secondary endpoints be provided in the top line release in the second quarter?
Thank you.
Question: Ryan Deschner - Raymond James - Analyst
: Thanks and congrats on the quarter. Can you remind us what went into the decision to offer BID dosing for the EXPAND study? And how would
you expect the dosing instructions to look on an expanded label in cholestatic pruritus patients? And then I have a follow-up.
Thanks.
Question: Ryan Deschner - Raymond James - Analyst
: Yeah. How big of an impact has the government shutdown been so far for things like genetic screening programs and other programs related to
Alagille and PFIC.
Thanks.
Question: Ryan McElroy - Leerink Partners LLC - Analyst
: You have Ryan on for [Mani]. Can you just talk a little bit about the pace of new PFIC adds that you guys saw in the third quarter compared to the
second quarter. I know you talked a lot about genetic testing and new patient diagnoses.
And then maybe more broadly, as you guys start to see consistent positive cash flow and you have several launches on the horizon. Maybe just
talk through your BD strategy about adding more products to the pipeline.
Thanks.
Question: Jonathan Wolleben - Citizens JMP Securities LLC - Analyst
: Hey, thanks for taking the question. Wondering if you guys are anticipating seeing similar disease-modifying effects over time with volixibat as
you saw with LIVMARLI in PSC and PBC. And if so, what would be the time frame? And do you think that would be a point of consideration for
adoption and use over time?
| 
